In this paper we consider patients of NSCLC or metastatic melanoma who are treated with CTLA-4 inhibitor (ipilimumab), and thus are at risk of severe adverse events, such as permanent damage to a vital organ. The gene discussed is CTLA4; the disease is metastatic melanoma.